MARKET

SRPT

SRPT

Sarepta Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

69.06
+0.57
+0.83%
Opening 09:30 05/26 EDT
OPEN
69.06
PREV CLOSE
68.49
HIGH
69.06
LOW
69.00
VOLUME
5.96K
TURNOVER
332.11K
52 WEEK HIGH
101.24
52 WEEK LOW
61.28
MARKET CAP
6.04B
P/E (TTM)
-16.2640
1D
5D
1M
3M
1Y
5Y
Ohio gene therapy industry gets 'buzz' – but needs to sell itself more
Cell and gene therapy researchers and companies in Ohio attract buzz, but a panel of experts said the industry needs to do better at promoting a statewide brand to attract talent.
American City Business Journals · 5d ago
Expert Ratings for Sarepta Therapeutics
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter:
Benzinga · 05/19 14:07
Morgan Stanley Adjusts Price Target for Sarepta Therapeutics to $74 From $77, Maintains Equalweight Rating
MT Newswires · 05/19 10:39
Wave Life Sciences slips as H.C. Wainwright lowers target
Then shares of Wave Life Sciences (NASDAQ:WVE) are trading lower in the morning hours Friday after H.C. Wainwright trimmed the price target of the clinical-stage genetic medicine company citing a
Seekingalpha · 05/13 14:18
Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q1
Bayer (BAYRY) beats estimates for both earnings and revenues in the first quarter of 2022.
Zacks · 05/10 14:56
Bullish insiders bet US$2.3m on Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Quite a few insiders have dramatically grown their holdings in Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) over the past...
Simply Wall St. · 05/09 15:49
Sarepta (SRPT) Q1 Earnings Beat, DMD Drugs' Sales Robust
Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the first quarter. Stock up in after-market trading.
Zacks · 05/05 13:31
--RBC Capital Adjusts Sarepta Therapeutics Price Target to $155 From $150, Maintains Outperform Rating
MT Newswires · 05/05 10:19
More
No Data
Learn about the latest financial forecast of SRPT. Analyze the recent business situations of Sarepta Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 21 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
42.86%Buy
23.81%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SRPT stock price target is 119.78 with a high estimate of 181.00 and a low estimate of 74.00.
High181.00
Average119.78
Low74.00
Current 70.47
EPS
Actual
Estimate
-1.51-1.13-0.76-0.38
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 509
Institutional Holdings: 78.63M
% Owned: 89.86%
Shares Outstanding: 87.50M
TypeInstitutionsShares
Increased
91
6.39M
New
51
3.92M
Decreased
119
6.38M
Sold Out
61
2.80M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.29%
Pharmaceuticals & Medical Research
+0.66%
Key Executives
Non-Executive Chairman/Independent Director
M. Kathleen Behrens
President/Chief Executive Officer/Director
Douglas Ingram
Chief Financial Officer/Executive Vice President
Ian Estepan
Executive Vice President/Chief Scientific Officer
Louise Rodino-Klapac
Executive Vice President
William Ciambrone
Senior Vice President/General Counsel/Secretary
Ryan Brown
Independent Director
Richard Barry
Independent Director
Mary Gray
Independent Director
Stephen Mayo
Independent Director
Claude Nicaise
Independent Director
Hans Wigzell
No Data
No Data
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy (DMD), Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. Its commercial products, EXONDYS 51 (eteplirsen) Injection, VYONDYS 53 (golodirsen) Injection and AMONDYS 45 (casimersen) Injection is for the treatment of DMD in patients, who have a confirmed mutation of the DMD gene that is amenable to exon 51, exon 53 and exon 45 skipping. It is also developing gene therapy programs for various forms of LGMDs. Its LGMD product candidate, SRP-9003, is designed to transfer a gene that codes for and restores beta-sarcoglycan protein.

Webull offers kinds of Sarepta Therapeutics Inc stock information, including NASDAQ:SRPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRPT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SRPT stock methods without spending real money on the virtual paper trading platform.